Nonalcoholic fatty liver disease

It has been reported that those patients with nonalcoholic fatty liver disease (NAFLD) are probably more common in those individuals with metabolic syndrome, which includes obesity and type 2 diabetes mellitus. The spectrum of NAFLD ranges from simple steatosis to steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). Of those with NASH, approximately 20% will go on to develop cirrhosis and hepatocellular carcinoma.

Metabolic disease; Endocrine disease

PNPLA3(polymorphism) [HSA:80339] [KO:K13534]

PMID:20373368

Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

Hepatology 51:1209-17 (2010)
DOI:10.1002/hep.23622

PMID:20684021

Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.

Hepatology 52:894-903 (2010)
DOI:10.1002/hep.23759

PMID:20648472

Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN

PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Hepatology 52:904-12 (2010)
DOI:10.1002/hep.23768